Literature DB >> 2420395

On the mechanism of Hb F elevations in the baboon by erythropoietic stress and pharmacologic manipulation.

D Lavelle, J DeSimone, P Heller, D Zwiers, L Hall.   

Abstract

Maximal fetal hemoglobin (Hb F) elevations in the baboon subsequent to phenyl hydrazine-induced hemolytic anemia, bleeding, bleeding plus hydroxyurea (HU), or cytosine arabinoside were two to three times lower than those achieved with bleeding plus 5-azacytidine (azaC). Because, in the baboon, maximal elevations in F cell numbers occurred with bleeding alone, changes in the levels of Hb F in hemolysates and in Hb F per F cell could be considered to be due to the administered drugs. Erythropoietic toxicity of azaC was minimal, making it unlikely that the marked elevations of Hb F were due to shifts in the population of erythroid progenitors and precursors and more likely that they were related to a biochemical effect of the drug on DNA. The data indicate marked DNA hypomethylation. This was also found to be associated, but to a much lesser extent, with the modest Hb F elevations after bleeding, hemolysis, and treatment with HU. This drug had greater erythroid toxicity than azaC, and it appeared that the Hb F elevations occurred mainly on the rebound from the early cytotoxicity. The explanation of the molecular DNA changes with this drug and in erythropoietic stress alone remains unknown.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2420395

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

1.  Sickle Cell Disease: Reappraisal of the Role of Foetal Haemoglobin Levels in the Frequency of Vaso-Occlusive Crisis.

Authors:  C Antwi-Boasiako; E Frimpong; G K Ababio; B Dzudzor; I Ekem; B Gyan; N A Sodzi-Tettey; D A Antwi
Journal:  Ghana Med J       Date:  2015-06

Review 2.  Fetal Hemoglobin Induction by Epigenetic Drugs.

Authors:  Donald Lavelle; James Douglas Engel; Yogen Saunthararajah
Journal:  Semin Hematol       Date:  2018-04-22       Impact factor: 3.851

Review 3.  Reawakening fetal hemoglobin: prospects for new therapies for the β-globin disorders.

Authors:  Daniel E Bauer; Sophia C Kamran; Stuart H Orkin
Journal:  Blood       Date:  2012-08-17       Impact factor: 22.113

4.  The LSD1 inhibitor RN-1 recapitulates the fetal pattern of hemoglobin synthesis in baboons (P. anubis).

Authors:  Angela Rivers; Kestis Vaitkus; Vinzon Ibanez; Maria Armila Ruiz; Ramasamy Jagadeeswaran; Yogen Saunthararajah; Shuaiying Cui; James D Engel; Joseph DeSimone; Donald Lavelle
Journal:  Haematologica       Date:  2016-02-08       Impact factor: 9.941

5.  Complex developmental patterns of histone modifications associated with the human beta-globin switch in primary cells.

Authors:  Mei Hsu; Christine A Richardson; Emmanuel Olivier; Caihong Qiu; Eric E Bouhassira; Christopher H Lowrey; Steven Fiering
Journal:  Exp Hematol       Date:  2009-05-19       Impact factor: 3.084

Review 6.  Epigenetic regulation of hemoglobin switching in non-human primates.

Authors:  Robert Molokie; Joseph DeSimone; Donald Lavelle
Journal:  Semin Hematol       Date:  2020-12-28       Impact factor: 3.851

Review 7.  Targeting sickle cell disease root-cause pathophysiology with small molecules.

Authors:  Yogen Saunthararajah
Journal:  Haematologica       Date:  2019-08-08       Impact factor: 9.941

Review 8.  A genome-wide meta-analysis yields 46 new loci associating with biomarkers of iron homeostasis.

Authors:  Steven Bell; Andreas S Rigas; Magnus K Magnusson; Egil Ferkingstad; Elias Allara; Gyda Bjornsdottir; Anna Ramond; Erik Sørensen; Gisli H Halldorsson; Dirk S Paul; Kristoffer S Burgdorf; Hannes P Eggertsson; Joanna M M Howson; Lise W Thørner; Snaedis Kristmundsdottir; William J Astle; Christian Erikstrup; Jon K Sigurdsson; Dragana Vuckovic; Khoa M Dinh; Vinicius Tragante; Praveen Surendran; Ole B Pedersen; Brynjar Vidarsson; Tao Jiang; Helene M Paarup; Pall T Onundarson; Parsa Akbari; Kaspar R Nielsen; Sigrun H Lund; Kristinn Juliusson; Magnus I Magnusson; Michael L Frigge; Asmundur Oddsson; Isleifur Olafsson; Stephen Kaptoge; Henrik Hjalgrim; Gudmundur Runarsson; Angela M Wood; Ingileif Jonsdottir; Thomas F Hansen; Olof Sigurdardottir; Hreinn Stefansson; David Rye; James E Peters; David Westergaard; Hilma Holm; Nicole Soranzo; Karina Banasik; Gudmar Thorleifsson; Willem H Ouwehand; Unnur Thorsteinsdottir; David J Roberts; Patrick Sulem; Adam S Butterworth; Daniel F Gudbjartsson; John Danesh; Søren Brunak; Emanuele Di Angelantonio; Henrik Ullum; Kari Stefansson
Journal:  Commun Biol       Date:  2021-02-03

9.  Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study.

Authors:  Robert Molokie; Donald Lavelle; Michel Gowhari; Michael Pacini; Lani Krauz; Johara Hassan; Vinzon Ibanez; Maria A Ruiz; Kwok Peng Ng; Philip Woost; Tomas Radivoyevitch; Daisy Pacelli; Sherry Fada; Matthew Rump; Matthew Hsieh; John F Tisdale; James Jacobberger; Mitch Phelps; James Douglas Engel; Santhosh Saraf; Lewis L Hsu; Victor Gordeuk; Joseph DeSimone; Yogen Saunthararajah
Journal:  PLoS Med       Date:  2017-09-07       Impact factor: 11.069

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.